StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP - Free Report) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock.
Tonix Pharmaceuticals Stock Down 8.4 %
Shares of TNXP stock traded down $0.03 on Wednesday, hitting $0.33. 80,811,016 shares of the stock were exchanged, compared to its average volume of 31,034,150. The business has a 50-day moving average of $0.23 and a 200 day moving average of $0.37. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $14.08. The firm has a market capitalization of $61.64 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
